Clinically meaningful improvement (≥20% fatigue severity reduction, measurable increase in physical activity tolerance) is reported in 45–55% of treated patients. Complete symptom resolution is rare; most benefit manifests as partial functional recovery enabling return to work or increased daily exertion capacity. Older patients (>60) and those with severe cardiopulmonary phenotypes show variable response; younger patients with predominantly neurological features may show better outcomes.
Published phase I safety data and small phase II trials (n=20–80 per arm) document symptomatic improvement in fatigue severity, exercise tolerance, and cognitive clarity in 40–55% of infused participants over 8–12 weeks. Objective markers—circulating microclot burden, endothelial dysfunction indices, IL-6 levels—show modest reduction in responder subgroups. One multicentre registry reports durable functional improvement (60-metre walk distance, sustained exertion capacity) persisting at 6 months in 45% of treated cohorts. Blinded controlled efficacy trials remain pending.
Am I a candidate? → · Long COVID: full overview → · Long COVID cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача